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Abstract
Cancer	 treatment,	 especially	 that	 for	 breast	 and	 lung	 cancer,	 has	 entered	 a	 new	
era	 and	 continues	 to	 evolve,	 with	 the	 development	 of	 genome	 analysis	 technol-
ogy	and	the	advent	of	molecular	targeted	drugs	including	tyrosine	kinase	inhibitors.	
Nevertheless,	acquired	drug	resistance	to	molecular	targeted	drugs	is	unavoidable,	
creating	a	clinically	challenging	problem.	We	recently	reported	the	antitumor	effect	
of	a	pan-HER	inhibitor,	afatinib,	against	human	epidermal	growth	factor	receptor	2	
(HER2)-amplified	gastric	cancer	cells.	The	purpose	of	the	present	study	was	to	iden-
tify	the	mechanisms	of	acquired	afatinib	resistance	and	to	investigate	the	treatment	
strategies	for	HER2-amplified	gastric	cancer	cells.	Two	afatinib-resistant	gastric	can-
cer	cell	 lines	were	established	from	2	HER2-amplified	cell	 lines,	N87	and	SNU216.	
Subsequently,	we	investigated	the	molecular	profiles	of	resistant	cells.	The	activation	
of	the	HER2	pathway	was	downregulated	in	N87-derived	resistant	cells,	whereas	it	
was	upregulated	in	SNU216-derived	resistant	cells.	In	the	N87-derived	cell	line,	both	
MET	and	AXL	were	activated,	and	combination	treatment	with	afatinib	and	cabozan-
tinib,	a	multikinase	inhibitor	that	inhibits	MET	and	AXL,	suppressed	the	cell	growth	
of	cells	with	acquired	 resistance	both	 in	vitro	and	 in	vivo.	 In	 the	SNU216-derived	
cell	 line,	YES1,	which	is	a	member	of	the	Src	family,	was	remarkably	activated,	and	
dasatinib,	a	Src	inhibitor,	exerted	a	strong	antitumor	effect	in	these	cells.	In	conclu-
sion,	we	identified	MET	and	AXL	activation	in	addition	to	YES1	activation	as	novel	
mechanisms	 of	 afatinib	 resistance	 in	HER2-driven	 gastric	 cancer.	Our	 results	 also	
indicated	that	treatment	strategies	targeting	individual	mechanisms	of	resistance	are	
key	to	overcoming	such	resistance.
K E Y W O R D S
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1  | INTRODUC TION
Thanks	 to	 the	 dramatic	 development	 of	 genome	 analysis	 technol-
ogy,	 including	 next-generation	 sequencing,	 cancer	 treatment	 has	
advanced	to	a	new	stage.	The	development	of	molecularly	targeted	
drugs	has	enabled	us	to	perform	precision	medicine.	However,	mo-
lecular	targeted	therapy	for	gastric	cancer	has	lagged	behind	that	for	
lung	cancer	and	breast	cancer,	despite	gastric	cancer	being	a	leading	
cause	of	death	from	cancer	worldwide.1
Human	epidermal	growth	factor	receptor	2	(HER2)	is	one	of	the	
few	therapeutic	target	genes	for	gastric	cancer,	and	trastuzumab	is	
the	only	anti–HER2	drug	with	established	clinical	evidence	for	this	
cancer	type2	at	present.	Lapatinib	is	the	only	HER2-targeting	small	
molecular	 drug	 for	 which	 phase	 III	 clinical	 trials	 have	 been	 per-
formed.	Neither	the	TyTAN	trial	nor	the	LOGiC	trial	demonstrated	
the	 superiority	 of	 lapatinib	 against	 HER2-amplified	 gastric	 can-
cer.3,4	Afatinib,	or	BIBW2992,	is	a	small	molecular	drug	that	binds	
to	the	kinase	domain	of	epidermal	growth	factor	receptor	(EGFR),	
HER2	and	HER4,	and	is	known	as	a	pan-HER	inhibitor.	Previously,	
we	 reported	 the	 antitumor	 effect	 of	 afatinib	 in	 HER2-amplified	
gastric	cancer.5	Although	both	trastuzumab	and	afatinib	are	HER2-
targeted	drugs,	 trastuzumab	 is	a	humanized	 IgG1	monoclonal	an-
tibody6	and	afatinib	 is	a	receptor	tyrosine	kinase	(RTK).7	Because	
the	 mechanisms	 of	 these	 2	 drugs	 are	 totally	 different,	 afatinib	
could	be	another	treatment	option	for	gastric	cancer.	However,	 it	
is	a	well-known	fact	 that	 the	emergence	of	 resistant	cancer	cells	
during	the	course	of	molecular	targeted	therapy	 is	a	 limitation	of	
molecularly	targeted	drugs.	Acquired	resistance	to	trastuzumab	in	
gastric	cancer	has	already	been	reported,8	and	drug	resistance	 is	
also	anticipated	to	be	a	problem	for	afatinib.	In	the	present	study,	
we	 established	 2	 afatinib-resistant	 gastric	 cancer	 cell	 lines	 and	
analyzed	 the	mechanisms	 of	 acquired	 resistance.	 In	 addition,	we	
investigated	 treatment	 strategies	 for	 these	 afatinib-resistant	 cell	
lines	so	as	to	contribute	to	the	development	of	precision	medicine	
for	gastric	cancer	patients.
2  | MATERIAL S AND METHODS
2.1 | Cell lines and reagents
Two	gastric	cancer	cell	lines,	NCI-N87	(N87)	and	SNU216,	were	used	
in	the	present	study.	N87	was	purchased	from	ATCC,	and	SNU216	
was	obtained	from	the	Korean	Cell	Line	Bank.	Both	cell	 lines	were	
cultured	in	RPMI	1640	media	supplemented	with	10%	FBS.	Afatinib,	
crizotinib	 and	 cabozantinib	 were	 purchased	 from	 Synkinase	 (San	
Diego,	CA,	USA),	Sigma-Aldrich	(St.	Louis,	MO,	USA),	and	ChemScene	
(Monmouth	 Junction,	 NJ,	 USA),	 respectively.	 Dasatinib	 was	 pur-
chased	from	Bristol-Myers	Squibb	(New	York,	NY,	USA).
2.2 | DNA and RNA extraction
Genomic	 DNAs	 of	 the	 cell	 lines	 were	 extracted	 using	 a	 DNeasy	
Blood	and	Tissue	Kit.	As	 for	 the	RNAs,	extraction	was	conducted	
using	an	RNeasy	Mini	Kit	(Qiagen,	Venlo,	the	Netherlands),	and	the	
RNAs	were	then	reversed	into	cDNA	using	the	High	Capacity	cDNA	
Reverse	Transcription	Kit	 (Thermo	Fisher	Scientific,	 San	 Jose,	CA,	
USA).	These	processes	were	performed	according	to	the	manufac-
turer's	instructions.
2.3 | Copy number and gene expression assay
To	 determine	 the	 copy	 number	 variation	 or	 the	 gene	 expres-
sion	of	various	genes,	we	performed	quantitative	real-time	PCR	
(qPCR)	(StepOnePlus	real-time	PCR	system,	Applied	Biosystems,	
Waltham,	MA,	USA)	using	the	ΔΔCT	method	and	a	Taqman	copy	
number	assay	and	Taqman	gene	expression	assay	(Thermo	Fisher	
Scientific),	 respectively.	 Both	 the	 copy	 number	 variation	 and	
gene	 expression	 analyses	were	 performed	 in	 triplicate.	We	de-
fined	the	copy	number	calculated	in	control	human	genomic	DNA	
(Promega,	Fitchburg,	WI,	USA)	as	2	and	amplification	as	values	
of	greater	than	4,	 in	accordance	with	the	protocol	of	our	previ-
ous	study9,10.	As	for	the	relative	gene	expression,	the	expression	
level	of	each	parent	cell	line	was	defined	as	1.
2.4 | Direct sequencing assay
A	direct	sequencing	assay	was	performed	to	 identify	acquired	on-
cogenic	mutations	in	HER2	or	PIK3CA	in	afatinib-resistant	cell	lines.	
Specifically,	exons	17	to	24,	which	include	the	coding	sequence	of	
the	 transmembrane	 domain	 and	 the	 kinase	 domain	 of	HER2,	 and	
exons	9	and	20	of	PIK3CA	were	analyzed	 in	the	direct	sequencing	
assay.	 The	 sequences	 of	 the	 primers	 used	 in	 this	 study	were	 the	
same	as	those	previously	reported.11-13
2.5 | Western blot analysis
Total	cell	lysate	extraction	and	western	blotting	were	performed	using	
a	previously	described	protocol.14,15	The	extracted	protein	was	quan-
titated	 using	 a	 protein	 assay	 (Bio-Rad	 Laboratories)	 and	 was	 trans-
ferred	to	a	membrane	using	a	transfer	system	(Bio-Rad	Laboratories,	
Hercules,	CA,	USA).	Then,	the	membranes	were	probed	with	primary	
antibodies	diluted	with	5%	BSA	overnight	at	4°C.	After	washing	more	
than	3	times	using	PBS-tween,	the	membranes	were	incubated	with	
the	secondary	antibodies	for	1	hour	at	25°C.	To	detect	specific	signals,	
we	examined	 the	membrane	using	 the	ECL	Prime	Western	Blotting	
Detection	 System	 (GE	 Healthcare)	 and	 LAS-3000	 (Fuji	 Film).	 The	
primary	antibodies	were	as	 follows:	p-HER2	 (Tyr1221/1222),	HER2,	
p-EGFR	(Tyr1068),	EGFR,	p-MAPK	(Erk1/2)	(Thr202/Tyr204),	MAPK	
(Erk1/2),	p-AKT	(Ser473),	AKT,	IGF-I	receptor	(IGF-1R),	p-IGF-I	recep-
tor	 (phospho-IGF-1R)	 (Tyr1135/1136),	 MET,	 p-MET(Tyr1234/1235),	
YES,	 Src,	 p-Src	 (Tyr416),	 ALDH1A1,	 ABCB1,	 E-cadherin,	 vimentin	
and	 p-AXL(Tyr702)	 (Cell	 Signaling	 Technology,	 Danvers,	 MA,	 USA),	
AXL	 (R&D	 Systems,	 Minneapolis,	 MN,	 USA),	 and	 actin	 (Santa	 Cruz	
Biotechnology,	Dallas,	TX,	USA).	The	secondary	antibodies	used	in	this	
study	were	as	 follows:	 goat	 anti–mouse	 IgG-HRP,	 goat	 anti-rat	 IgG-
HRP	and	donkey	anti–goat	IgG-HRP	(Santa	Cruz	Biotechnology).
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2.6 | Phospho‐receptor tyrosine kinase array
We	evaluated	the	phosphorylation	of	42	distinct	RTK	in	the	total	cell	
lysate	using	a	Human	Phospho-Receptor	Tyrosine	Kinase	(RTK)	Array	
Kit	 (R&D	Systems).	The	total	cell	 lysates	were	extracted	in	the	same	
manner	as	for	western	blotting,	and	the	phosphorylation	of	the	RTK	
was	analyzed	according	to	the	manufacturer's	instructions.
2.7 | Cell viability assay and combination index
The	antitumor	effects	of	the	drugs	were	determined	using	an	MTS	
assay.	The	IC50	value,	which	is	the	drug	concentration	used	to	inhibit	
the	cell	proliferation	by	50%,	was	calculated	based	on	the	results	of	
the	MTS	assay.	In	the	MTS	assay,	the	cells	were	equally	seeded	on	a	96-
well	plate	(2000	cells/well),	and	drug	dilutions	were	added	12	hours	
later.	The	concentrations	of	 the	drugs	 ranged	 from	0.16	nmol/L	 to	
10 μmol/L.	After	3	days	of	medication,	the	cell	proliferation	was	de-
termined	using	CellTiter	96	AQueous	bromide	One	Solution	Reagent	
(Promega).	In	cases	where	2	drugs	were	administered	simultaneously	
as	a	combination	therapy,	we	used	the	same	concentration	for	both	
drugs.	 The	 synergism	of	 the	2	drugs	was	 calculated	 as	 a	 combina-
tion	index	(CI)	based	on	the	result	of	the	MTS	assay	using	Calcusyn	
software	 (Biosoft,	Cambridge,	UK).	Combination	therapy	effects	of	
CI	<	1,	CI	=	1	and	CI	>	1	were	defined	as	synergistic	effects,	additive	
effects	and	antagonistic	effects,	respectively.
2.8 | Statistical analysis
The	statistical	analysis	was	conducted	using	EZR	version	1.35	(Jichi	
Medical	University,	Saitama,	Japan)	and	the	R	Commander	Graphical	
User	Interface	(The	R	Foundation	for	Statistical	Computing,	Vienna,	
Austria).16	Differences	between	2	groups	were	evaluated	using	a	t 
test,	and	differences	with	a	2-tailed	P-value	less	than	0.05	were	con-
sidered	statistically	significant.
2.9 | Xenograft mouse model
For	the	animal	experimental	procedures,	all	the	mice	were	handled	
in	 accordance	with	 the	Policy	on	 the	Care	 and	Use	of	 Laboratory	
Animals,	 Okayama	 University.	 Six-week	 old	 mice	 were	 purchased	
from	CLEA	Japan	(Tokyo,	Japan).	N87-AR	(N87-derived	afatinib-re-
sistant	cell	line)	and	SNU216-AR	(SNU216-derived	afatinib-resistant	
cell	line)	cells	(approximately	1.0	×	106)	were	suspended	in	50	μL	of	
RPMI	 1640	 and	 50	 μL	 of	 Corning	Matrigel	 Basement	Membrane	
Matrix	 (Corning,	NY,	USA),	 then	 subcutaneously	 transplanted	at	2	
locations	on	the	backside	of	each	mouse.	Because	the	tumor	growth	
of	SNU216-AR	was	extremely	 slow,	we	continued	 the	experiment	
using	N87-AR	only.	The	experimental	mice	were	randomly	divided	
into	 3	 groups:	 an	 afatinib	 group	 (20	 mg/kg/day),	 a	 combination	
therapy	group	 (afatinib,	 20	mg/kg/day	 and	 cabozantinib,	100	mg/
kg/day)	 and	 a	 control	 group	 (placebo).	 The	 drugs	 were	 diluted	 in	
0.5	w/v	 (%)	methyl	 cellulose	 (Wako	Pure	Chemical	 Industries)	 and	
were	orally	administered	5	 times	a	week	 for	3	weeks.	We	started	
drug	administration	 after	 confirming	 that	 the	 tumor	had	begun	 to	
increase	by	palpation	and	tumor	diameter	measurement.	In	the	con-
trol	group,	mice	were	treated	with	100	μL	of	methyl	cellulose	only,	
5	times	per	week.	The	tumor	volume	was	measured	using	calipers	
and	was	 calculated	 using	 the	 following	 empirical	 formula:	Volume	
(mm3)	=	length	(longest	diameter)	×	width	(shortest	diameter)2	×	0.5.
3  | RESULTS
3.1 | Establishment of afatinib‐resistant gastric 
cancer cell lines
Two	 gastric	 cancer	 cell	 lines,	 N87	 and	 SNU216,	were	 exposed	 to	 a	
high	concentration	of	afatinib	(2	μmol/L)	intermittently	for	more	than	
6	months,	 and	afatinib-resistant	 cell	 lines	 (N87-AR	and	SNU216-AR)	
were	established	from	each	parent	cell	line.	Both	parent	cell	lines	are	
HER2-amplified	and	highly	sensitive	to	afatinib.	The	drug	sensitivities	
were	evaluated	using	the	IC50	value	calculated	from	the	result	of	the	
MTS	assay	 to	confirm	 the	successful	establishment	of	 resistant	cells	
(Table 1).
3.2 | Gene alterations and activation of HER2 in 
afatinib‐resistant cell lines
Initially,	we	compared	the	gene	alterations,	expression,	and	activa-
tion	of	HER2	in	afatinib-resistant	cells	with	those	of	the	parent	cells.	
The	copy	number	assay	showed	that	both	resistant	cells	maintained	
the	 amplification	of	HER2	 (Figure	1A),	 but	 the	gene	expression	of	
HER2	 was	 significantly	 downregulated	 compared	 with	 that	 in	 the	
parent	 cells	 (Figure	 1B).	 Likewise,	 western	 blotting	 demonstrated	
the	 downregulation	 of	 total	 HER2	 in	 both	 afatinib-resistant	 cell	
lines.	 In	 contrast,	 there	was	a	clear	difference	 in	 the	activation	of	
HER2	and	down-signal	pathway	molecules	between	the	2	resistant	
cell	types:	phosphorylated	HER2	(p-HER2)	and	signals	via	HER2,	p-
ERK	and	p-AKT	were	downregulated	in	N87-AR,	while	p-HER2	was	
upregulated	in	SNU216-AR,	and	this	cell	type	maintained	the	acti-
vation	of	AKT	and	ERK	 (Figure	1C).	No	oncogenic	mutations	were	
detected	in	the	transmembrane	and	kinase	domains	of	HER2	using	
direct	sequencing.
Cell line Characteristics HER2 amplification IC50 (nmol/L)
N87 Parental	cell	line Yes 3.1
N87-AR Afatinib	resistant	cell	line Yes 1089.6
SNU216 Parental	cell	line Yes 29.0
SNU216-AR Afatinib	resistant	cell	line Yes 4431.7
TA B L E  1   IC50	value	for	afatinib	and	
HER2	alteration	in	parental	and	afatinib-
resistant	cell	lines
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3.3 | Activation of MSP‐R, AXL and c‐Ret in 
resistant cell lines
We	evaluated	the	activation	of	RTK	using	a	phospho-RTK	array	to	nar-
row	down	the	candidate	mechanisms	of	resistance.	The	results	of	the	
resistant	cells	were	compared	with	those	of	the	parental	cells.	In	N87-
AR,	the	activation	of	MSP-R,	which	reportedly	forms	a	hetero-dimer	
with	MET,17	was	upregulated.	In	addition	to	MSP-R,	the	activation	of	
AXL	and	c-RET	was	also	upregulated.	 In	particular,	 the	upregulation	
of	AXL	was	remarkable.	In	contrast,	no	clear	upregulation	of	RTK	was	
observed	in	SNU216-AR	compared	with	the	parental	cells	(Figure	1D).
3.4 | Acquisition of MET and AXL amplification in 
afatinib‐resistant cell lines
Based	on	the	results	of	the	RTK	array,	we	performed	a	copy	num-
ber	assay	of	MET and AXL	in	N87-AR;	MET	was	clearly	amplified	in	
N87-AR	 (Figure	2A),	and	no	significant	difference	was	detected	 in	
the	 copy	number	 variation	of	AXL.	Western	blotting	 showed	 that	
total	and	phosphorylated	MET	were	also	dramatically	upregulated	
in	N87-AR.	In	addition,	we	confirmed	the	upregulation	of	AXL	using	
western	blotting	(Figure	2B).
Based	on	the	revealed	mechanisms	of	resistance,	we	tried	to	es-
tablish	a	therapeutic	strategy	for	afatinib-resistant	cells.	To	overcome	
the	resistance	caused	by	MET	amplification,	we	administered	a	MET	
inhibitor	 and/or	 afatinib	 to	 N87-AR.	 The	 effect	 of	 the	 anti–tumor	
drugs	was	estimated	using	an	MTS	assay,	and	we	used	crizotinib	or	
cabozantinib	as	MET	inhibitors.	Besides	the	activation	of	MET,	crizo-
tinib	reportedly	inhibits	ALK	and	cabozantinib	inhibits	AXL,	RET,	KIT,	
FLT3	 and	 VEGFR2.	 The	 effect	 of	 either	 crizotinib	 or	 cabozantinib	
alone	was	insufficient	to	suppress	cell	proliferation	of	N87-AR,	but	
both	crizotinib	and	cabozantinib	restored	the	sensitivity	to	afatinib	
(Figure	2C).	These	combination	therapies	were	judged	to	have	a	syn-
ergistic	 effect	 based	 on	 their	CI	 (Figure	 S1A,B).	When	 the	 2	MET	
inhibitors	 were	 compared,	 cabozantinib	 was	 more	 effective	 than	
crizotinib	against	N87-AR,	and	 the	 IC50	 value	of	combination	 ther-
apy	with	afatinib	and	cabozantinib	was	42.5	nmol/L.	Subsequently,	
we	performed	western	blotting	to	examine	the	effect	of	afatinib	and	
cabozantinib	on	the	signaling	pathway	in	N87-AR.	As	expected,	afati-
nib	downregulated	p-HER2,	and	cabozantinib	downregulated	p-MET	
F I G U R E  1  Difference	in	HER2 
status	and	activation	of	RTK	between	
parental	and	afatinib-resistant	cells.	
A,	Copy	number	variation	and	gene	
expression	of	HER2	in	parental	and	
afatinib-resistant	cell	lines.	Both	resistant	
cell	lines,	N87-AR	and	SNU216-AR,	
continued	to	exhibit	HER2	amplification.	
B,	Relative	gene	expression	of	HER2	
in	parental	and	afatinib-resistant	cell	
lines.	Gene	expression	was	significantly	
downregulated	in	both	afatinib-resistant	
cell	lines.	C,	Activation	of	HER2	and	
down-signal	pathway	molecules	evaluated	
using	western	blotting.	HER2	and	down-
stream	molecules	were	downregulated	
in	N87-AR,	and	p-HER2	was	upregulated	
in	SNU216-AR.	D,	Phospho-RTK	assay	
of	parental	and	resistant	cells.	The	
phosphorylation	of	MSP-R,	c-RET	and	
AXL	were	upregulated	in	N87-AR
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and	p-AXL	(Figure	2D).	Neither	afatinib	nor	cabozantinib	monother-
apy	suppressed	the	activation	of	AKT	and	ERK,	but	the	combination	
therapy,	nonetheless,	downregulated	both	AKT	and	ERK.
3.5 | Acquisition of Yes1 amplification in afatinib‐
resistant cell lines
Next,	 we	 performed	 a	 copy	 number	 assay	 of	 YES1,	 a	 member	 of	
the	 Src	 family,	 in	N87-AR	 and	 SNU216-AR.	Yes1	was	 amplified	 in	
SNU216-AR	 but	 not	 in	N87-AR	 (Figure	 3A).	 The	 protein	 levels	 of	
total	and	phosphorylated	Src	and	Yes	were	markedly	upregulated	in	
SNU216-AR	(Figure	3B).
Next,	we	tried	to	overcome	afatinib-resistance	induced	by	Yes1 
amplification	 in	SNU216-AR.	Similar	to	our	strategy	for	N87-AR,	
we	used	the	Src	inhibitor	dasatinib	and/or	afatinib	in	SNU216-AR.	
Unlike	 crizotinib	 or	 cabozantinib	 in	 the	 MET-amplified	 resistant	
cells,	 dasatinib	monotherapy	was	effective	 in	 the	Yes1	 amplified	
cells.	Combination	therapy	with	afatinib	produced	a	dramatic	ef-
fect,	and	the	IC50	value	was	as	low	as	10.3	nmol/L	(Figure	3C).	This	
combination	therapy	was	also	considered	to	be	synergistic	(Figure	
S1C).	Regarding	the	signaling	pathway,	afatinib	downregulated	p-
HER2,	 and	dasatinib	downregulated	p-Src,	 as	 expected.	Afatinib	
suppressed	 the	 activation	 of	 AKT	 in	 afatinib-resistant	 cells,	 and	
dasatinib	 also	 downregulated	 p-HER2	 unexpectedly.	 Although	
neither	 afatinib	 nor	 dasatinib	monotherapy	 suppressed	 the	 acti-
vation	of	ERK,	the	combination	therapy	of	these	drugs	downregu-
lated	it	(Figure	3D).	Because	dasatinib	downregulated	p-HER2,	we	
also	evaluated	the	effect	of	dasatinib	in	the	SNU216	parental	cell	
line	 and	 found	 that	 dasatinib	monotherapy	was	 effective	 in	 this	
cell	line	as	well	(Figure	3E).
3.6 | Antitumor effect of cabozantinib in a 
xenograft mouse model
Based	on	the	results	of	an	 in	vitro	assay,	we	performed	an	 in	vivo	
assay	 to	examine	 the	effect	of	 combination	 therapy	using	afatinib	
and	cabozantinib	in	N87-AR.	The	combination	therapy	had	a	signifi-
cant	antitumor	effect	against	N87-AR	(Figure	4A,B).	Afatinib	also	had	
F I G U R E  2   MET	amplification	and	AXL	
overexpression	in	the	afatinib-resistant	
cell	lines	N87-AR.	A,	Copy	number	assay	
of	MET and AXL. MET	was	amplified	in	
N87-AR.	B,	The	activation	of	MET	and	
AXL	was	analyzed	using	western	blotting.	
Total	and	phosphorylated	MET	and	AXL	
were	clearly	upregulated	in	N87-AR.	C,	
Drug	sensitivities	to	afatinib	and/or	MET	
inhibitors	in	N87-AR	as	evaluated	using	
an	MTS	assay.	Combination	treatment	
with	afatinib	and	cabozantinib	had	a	
remarkable	effect	in	N87-AR.	D,	Effects	
of	afatinib	and/or	cabozantinib	on	HER2	
and	down-signal	pathway	molecules	
in	N87-AR.	The	combination	therapy	
suppressed	the	activation	of	HER2,	MET,	
AXL,	ERK,	and	AKT.	The	concentrations	
of	afatinib	and	cabozantinib	were	both	
100	nmol/L,	and	the	medication	was	
performed	for	24	h
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a	mild	antitumor	effect	even	when	administered	as	a	single	agent,	
although	the	effect	was	limited	compared	with	its	effect	when	com-
bined	with	cabozantinib.	To	evaluate	the	tolerability	of	the	molecu-
larly	targeted	drugs,	the	body	weights	of	the	mice	were	measured	
before	and	after	treatment.	No	significant	changes	 in	body	weight	
were	observed,	suggesting	that	monotherapy	with	these	drugs	was	
tolerable	(Figure	4C).
4  | DISCUSSION
In	 this	 study,	 we	 established	 2	 afatinib-resistant	 cell	 lines	 using	
HER2-amplified	gastric	cancer	cell	lines	and	identified:	(i)	MET	ampli-
fication	with	AXL	upregulation	and	(ii)	YES1	amplification	as	mecha-
nisms	of	resistance.	Moreover,	we	investigated	treatment	strategies	
for	afatinib-resistant	cell	lines	and	showed	that:	(i)	combination	ther-
apy	with	 afatinib	 and	 cabozantinib	 and	 (ii)	 dasatinib	monotherapy	
were	 capable	 of	 overcoming	 the	 abovementioned	mechanisms	 of	
resistance,	respectively.
The	 gene	 amplification	 of	MET	 has	 already	 been	 reported	 as	 a	
mechanism	of	afatinib	resistance	 in	 lung	cancer.18	AXL	upregulation	
has	also	been	 reported	as	a	mechanism	of	 resistance	 to	TKI.19-21 In 
N87-AR,	a	clear	difference	between	the	effects	of	2	MET	inhibitors,	
crizotinib	and	cabozantinib,	was	seen	when	these	inhibitors	were	used	
in	combination	with	afatinib,	as	only	cabozantinib	downregulated	the	
activation	of	AXL.	This	phenomenon	suggests	that	not	only	the	activa-
tion	of	MET	but	also	the	activation	of	AXL	plays	a	pivotal	role	in	the	ac-
quisition	of	afatinib	resistance	in	this	cell	line.	In	addition,	cabozantinib	
also	inhibited	the	activation	of	RET,	which	was	slightly	upregulated	in	
N87-AR.	Based	on	the	fact	that	the	heterogeneity	of	gastric	cancer	is	a	
challenging	and	significant	issue,22,23	the	inhibition	of	multiple	targets	
could	be	an	especially	effective	strategy	for	this	cancer	type.
Previously,	 we	 reported	 that	 YES1	 amplification	 mediates	
resistance	 to	 lapatinib,	 a	 dual	 inhibitor	 of	 EGFR	 and	 HER2,	 in	
F I G U R E  3  YES1	amplification	in	the	
afatinib-resistant	cell	line	SNU216-AR.	
A,	Copy	number	assay	of	YES1. YES1 
was	amplified	in	SNU216-AR.	B,	
Activation	of	Src	and	expression	of	YES1	
as	evaluated	using	western	blotting.	
Total	and	phosphorylated	Src	and	YES1	
were	upregulated	in	SNU216-AR.	C,	
Drug	sensitivities	to	afatinib	and/or	Src	
inhibitors	in	SNU216-AR	as	calculated	
using	an	MTS	assay.	Not	only	the	
combination	treatment	of	afatinib	and	
dasatinib,	but	also	dasatinib	monotherapy	
had	a	remarkable	effect	in	SNU216-AR.	
D,	Effects	of	afatinib	and/or	dasatinib	on	
HER2	and	down-signal	pathway	molecules	
in	SNU216-AR.	The	combination	therapy	
suppressed	the	activation	of	HER2,	
Src,	ERK	and	AKT.	The	concentrations	
of	afatinib	and	dasatinib	were	both	
100	nmol/L,	and	the	medication	was	
performed	for	24	h.	E,	Effects	of	dasatinib	
and/or	afatinib	in	SNU216	parental	cells.	
The	combination	therapy	was	dramatically	
effective,	but	both	afatinib	and	dasatinib	
monotherapy	also	showed	strong	
antitumor	effects
     |  2555YOSHIOKA et Al.
HER2-amplified	breast	cancer.24	Based	on	the	results	of	this	study,	
we	 are	 convinced	 that	YES1	plays	 an	 important	 role	 in	 the	 acqui-
sition	of	 resistance	 in	HER2-amplified	malignant	 tumors.	 Indeed,	 a	
recent	report	of	clinical	genomic	sequencing	of	human	lung	cancer	
samples	obtained	after	the	acquisition	of	resistance	to	EGFR	inhibi-
tors	has	revealed	the	amplification	of	YES1.25
Regarding	other	mechanisms	of	resistance,	we	examined	whether	
the	resistant	cells	acquired	epithelial-mesenchymal	transition	(EMT)	
features,	cancer	stem	cell	(CSC)-like	features,10	the	upregulation	of	
IGF1R	or	 IGFBP,26,27	or	oncogenic	mutations	of	PIK3CA28-30 based 
on	previously	published	articles.	The	acquisition	of	EMT	or	CSC-like	
features	was	evaluated	using	western	blotting	 to	examine	 the	ex-
pressions	of	E-cadherin,	vimentin	and	ALDH1A1.	However,	no	clear	
differences	 between	 the	 parental	 cells	 and	 the	 afatinib-resistant	
cells	 were	 found	 in	 these	 analyses.	 Taking	 into	 consideration	 the	
fact	 that	 the	 acquisition	of	EMT	or	CSC-like	 features	 is	 the	major	
mechanism	of	afatinib-resistance	in	lung	cancer,	the	mechanisms	of	
resistance	may	vary	according	to	cancer	type.31
Afatinib	monotherapy	had	a	slight	antitumor	effect	against	afa-
tinib-resistant	N87-AR	cells	in	an	in	vivo	assay,	but	not	in	vitro.	We	
supposed	that	 the	microenvironment,	 including	the	existence	of	 fi-
broblasts	or	stromal	cells,	promoted	the	efficacy	of	afatinib	treatment,	
although	 the	 detailed	 mechanism	 remains	 unclear.	 Nevertheless,	
the	 effect	 of	 afatinib	 against	N87-AR	was	 quite	 limited,	 compared	
with	 the	 dramatic	 effect	 of	 afatinib	 in	 the	 parental	 cell	 line,	N87.5 
Combination	therapy	with	afatinib	and	cabozantinib	exerted	an	over-
whelmingly	superior	effect,	compared	with	afatinib	monotherapy.
Diarrhea	and	rash	have	been	reported	as	the	most	frequent	ad-
verse	events	associated	with	afatinib	treatment,32,33	while	diarrhea,	
hypertension	 and	 palmar-plantar	 erythrodysaesthesia	 syndrome	
(PPES)	have	been	reported	for	cabozantinib.34,35	In	this	experiment,	
the	appearance	of	these	adverse	events	was	a	concern,	because	the	
combination	of	these	2	agents	might	have	increased	the	severity	of	
such	events.	However,	 severe	adverse	events	were	not	 suggested	
in	our	experiment,	based	on	the	weight	loss	of	the	examined	mice,	
while	a	strong	antitumor	effect	was	observed.
F I G U R E  4  Effects	of	combination	
therapy	with	afatinib	and	cabozantinib	in	
N87-AR	in	vivo.	A,	Combination	therapy	
had	a	dramatic	effect	in	N87-AR.	B,	
Photographs	of	a	tumor	resected	from	
a	xenograft	model,	taken	on	day	21.	C,	
Body	weight	of	the	mice.	No	weight	losses	
were	observed	in	any	of	the	groups
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In	this	study,	dasatinib	suppressed	the	activation	of	HER2	in	ad-
dition	 to	 Src.	 Some	 articles	 have	 already	 reported	 the	 interaction	
of	 Src	 family	proteins	 and	HER2.36,37	This	 phenomenon	might	 ex-
plain	the	reason	why	dasatinib	monotherapy	had	a	remarkable	an-
titumor	 effect	 against	 the	YES1	 and	HER2-amplified	 resistant	 cell	
line	SNU216-AR.	In	contrast,	afatinib	downregulated	not	only	phos-
phorylated-HER2,	but	also	total-HER2,	unlike	dasatinib.	Afatinib	 is	
thought	to	inhibit	the	activation	of	HER2	more	strongly	than	dasat-
inib	and	to	kill	cells	 in	which	the	gene	expression	of	HER2	is	more	
strongly	activated.	Consequently,	afatinib	was	capable	of	downreg-
ulating	the	total	HER2.	To	confirm	that	dasatinib	inhibited	the	acti-
vation	of	both	HER2	and	Src,	we	examined	the	antitumor	effect	of	
dasatinib	against	SNU216	parental	cells	and	observed	that	SNU216	
was	also	highly	sensitive	to	dasatinib.	Thus,	dasatinib	could	poten-
tially	be	another	 therapeutic	option	 in	 the	 treatment	of	HER2-am-
plified	gastric	cancer	cells,	and	not	just	for	afatinib-resistant	cells.
In	 conclusion,	 we	 identified:	 (i)	MET	 amplification	 with	 AXL	
overexpression	and	 (ii)	Yes1	amplification	as	mechanisms	of	afa-
tinib	resistance	in	gastric	cancer	cells.	Combination	therapy	with	
afatinib	 and	 cabozantinib	 or	 dasatinib	monotherapy	were	 capa-
ble	 of	 overcoming	 the	 abovementioned	 resistance	mechanisms,	
respectively.	As	precision	medicine	continues	to	evolve	in	cancer	
treatment,	we	are	convinced	that	these	findings	will	contribute	to	
the	development	of	treatment	strategies	for	patients	with	gastric	
cancer.
DISCLOSURE
The	authors	have	no	conflict	of	interest.
ORCID
Kazuhiko Shien  https://orcid.org/0000-0002-4959-4220 
Hiromasa Yamamoto  https://orcid.org/0000-0002-5330-5460 
Toshiyoshi Fujiwara  https://orcid.org/0000-0002-5377-6051 
Shinichi Toyooka  https://orcid.org/0000-0002-7588-6745 
R E FE R E N C E S
	 1.	 Torre	 LA,	 Bray	 F,	 Siegel	 RL,	 Ferlay	 J,	 Lortet-Tieulent	 J,	 Jemal	 A.	
Global	cancer	statistics,	2012.	CA Cancer J Clin	2015;65:87-108.
	 2.	 Bang	YJ,	Van	Cutsem	E,	Feyereislova	A,	et	al.	Trastuzumab	in	com-
bination	with	chemotherapy	versus	chemotherapy	alone	for	treat-
ment	 of	 HER2-positive	 advanced	 gastric	 or	 gastro-oesophageal	
junction	 cancer	 (ToGA):	 a	 phase	 3,	 open-label,	 randomised	 con-
trolled	trial.	Lancet.	2010;376:687-697.
	 3.	 Satoh	T,	Xu	RH,	Chung	HC,	et	al.	Lapatinib	plus	paclitaxel	versus	
paclitaxel	alone	in	the	second-line	treatment	of	HER2-amplified	ad-
vanced	gastric	cancer	in	Asian	populations:	TyTAN–a	randomized,	
phase	III	study.	J Clin Oncol.	2014;32:2039-2049.
	 4.	 Hecht	 JR,	 Bang	 YJ,	 Qin	 SK,	 et	 al.	 Lapatinib	 in	 combination	 with	
capecitabine	 plus	 oxaliplatin	 in	 human	 epidermal	 growth	 factor	
receptor	2-positive	advanced	or	metastatic	gastric,	esophageal,	or	
gastroesophageal	 adenocarcinoma:	 TRIO-013/LOGiC–A	 random-
ized	phase	III	trial.	J Clin Oncol.	2016;34:443-451.
	 5.	 Yoshioka	 T,	 Shien	 K,	 Namba	 K,	 et	 al.	 Antitumor	 activity	 of	 pan-
HER	 inhibitors	 in	 HER2-positive	 gastric	 cancer.	 Cancer Sci. 
2018;109:1166-1176.
	 6.	 Hudis	 CA.	 Trastuzumab–mechanism	 of	 action	 and	 use	 in	 clinical	
practice.	N Engl J Med.	2007;357:39-51.
	 7.	 Agus	DB,	Terlizzi	E,	Stopfer	P,	Amelsberg	A,	Gordon	MS.	A	phase	
I	dose	escalation	study	of	BIBW	2992,	an	irreversible	dual	EGFR/
HER2	receptor	tyrosine	kinase	inhibitor,	in	a	continuous	schedule	in	
patients	with	advanced	solid	tumours.	J Clin Oncol.	2006;24:2074.
	 8.	 Roukos	DH.	Targeting	gastric	cancer	with	trastuzumab:	new	clinical	
practice	and	innovative	developments	to	overcome	resistance.	Ann 
Surg Oncol.	2010;17:14-17.
	 9.	 Soh	 J,	 Okumura	 N,	 Lockwood	WW,	 et	 al.	 Oncogene	 mutations,	
copy	number	gains	and	mutant	allele	specific	imbalance	(MASI)	fre-
quently	occur	together	in	tumor	cells.	PLoS ONE.	2009;4:e7464.
	10.	 Shien	 K,	 Toyooka	 S,	 Yamamoto	 H,	 et	 al.	 Acquired	 resistance	 to	
EGFR	inhibitors	is	associated	with	a	manifestation	of	stem	cell-like	
properties	in	cancer	cells.	Can Res.	2013;73:3051-3061.
	11.	 Yamamoto	H,	Higasa	K,	Sakaguchi	M,	et	al.	Novel	germline	muta-
tion	in	the	transmembrane	domain	of	HER2	in	familial	lung	adeno-
carcinomas. J Natl Cancer Inst.	2014;106:djt338.
	12.	 Shigematsu	H,	 Takahashi	 T,	 Nomura	M,	 et	 al.	 Somatic	mutations	
of	 the	 HER2	 kinase	 domain	 in	 lung	 adenocarcinomas.	 Can Res. 
2005;65:1642-1646.
	13.	 Yamamoto	 H,	 Shigematsu	 H,	 Nomura	 M,	 et	 al.	 PIK3CA	 muta-
tions	 and	 copy	 number	 gains	 in	 human	 lung	 cancers.	 Can Res. 
2008;68:6913-6921.
	14.	 Shien	 K,	 Ueno	 T,	 Tsukuda	 K,	 et	 al.	 Knockdown	 of	 the	 epidermal	
growth	factor	receptor	gene	to	investigate	its	therapeutic	potential	
for	the	treatment	of	non-small-cell	 lung	cancers.	Clin Lung Cancer. 
2012;13:488-493.
	15.	 Shien	K,	 Toyooka	 S,	 Ichimura	K,	 et	 al.	 Prognostic	 impact	 of	 can-
cer	 stem	 cell-related	 markers	 in	 non-small	 cell	 lung	 cancer	 pa-
tients	 treated	 with	 induction	 chemoradiotherapy.	 Lung Cancer. 
2012;77:162-167.
	16.	 Kanda	 Y.	 Investigation	 of	 the	 freely	 available	 easy-to-use	 soft-
ware	 ‘EZR’	 for	 medical	 statistics.	 Bone Marrow Transplant. 
2013;48:452-458.
	17.	 Yao	 HP,	 Zhou	 YQ,	 Zhang	 R,	 Wang	 MH.	 MSP-RON	 signalling	 in	
cancer:	 pathogenesis	 and	 therapeutic	 potential.	 Nat Rev Cancer. 
2013;13:466-481.
	18.	 Torigoe	H,	Shien	K,	Takeda	T,	et	al.	Therapeutic	strategies	for	afa-
tinib-resistant	lung	cancer	harboring	HER2	alterations.	Cancer Sci. 
2018;109:1493-1502.
	19.	 Namba	K,	Shien	K,	Takahashi	Y,	et	al.	Activation	of	AXL	as	a	preclin-
ical	acquired	resistance	mechanism	against	osimertinib	 treatment	
in	 EGFR-mutant	 non-small	 cell	 lung	 cancer	 cells.	Mol Cancer Res. 
2018;17:499-507.
	20.	 Zhou	L,	Liu	XD,	Sun	M,	et	al.	Targeting	MET	and	AXL	overcomes	
resistance	 to	 sunitinib	 therapy	 in	 renal	 cell	 carcinoma.	Oncogene. 
2016;35:2687-2697.
	21.	 Rho	JK,	Choi	YJ,	Kim	SY,	et	al.	MET	and	AXL	inhibitor	NPS-1034	ex-
erts	efficacy	against	lung	cancer	cells	resistant	to	EGFR	kinase	inhib-
itors	because	of	MET	or	AXL	activation.	Can Res.	2014;74:253-262.
	22.	 Wong	SS,	Kim	KM,	Ting	JC,	et	al.	Genomic	landscape	and	genetic	
heterogeneity	 in	 gastric	 adenocarcinoma	 revealed	 by	 whole-ge-
nome	sequencing.	Nat Commun. 2014;5:5477.
	23.	 Ooi	WF,	Xing	M,	Xu	C,	et	al.	Epigenomic	profiling	of	primary	gas-
tric	 adenocarcinoma	 reveals	 super-enhancer	 heterogeneity.	 Nat 
Commun.	2016;7:12983.
	24.	 Takeda	T,	Yamamoto	H,	Kanzaki	H,	et	al.	Yes1	signaling	mediates	the	
resistance	 to	Trastuzumab/Lap	atinib	 in	breast	cancer.	PLoS ONE. 
2017;12:e0171356.
	25.	 Fan	PD,	Narzisi	G,	 Jayaprakash	AD,	 et	 al.	YES1	amplification	 is	 a	
mechanism	of	acquired	resistance	to	EGFR	inhibitors	identified	by	
     |  2557YOSHIOKA et Al.
transposon	mutagenesis	 and	clinical	 genomics.	Proc Natl Acad Sci 
USA.	2018;115:E6030-e8.
	26.	 Rowe	 DL,	 Ozbay	 T,	 Bender	 LM,	 Nahta	 R.	 Nordihydroguaiaretic	
acid,	 a	 cytotoxic	 insulin-like	 growth	 factor-I	 receptor/HER2	 in-
hibitor	 in	 trastuzumab-resistant	 breast	 cancer.	 Mol Cancer Ther. 
2008;7:1900-1908.
	27.	 Evdokimova	V,	Tognon	CE,	Benatar	T,	 et	 al.	 IGFBP7	binds	 to	 the	
IGF-1	receptor	and	blocks	its	activation	by	insulin-like	growth	fac-
tors.	Sci Signal. 2012;5:ra92.
	28.	 Wu	X,	 Renuse	 S,	 Sahasrabuddhe	NA,	 et	 al.	 Activation	 of	 diverse	
signalling	pathways	by	oncogenic	PIK3CA	mutations.	Nat Commun. 
2014;5:4961.
	29.	 Chandarlapaty	S,	Sakr	RA,	Giri	D,	et	al.	Frequent	mutational	acti-
vation	 of	 the	 PI3K-AKT	 pathway	 in	 trastuzumab-resistant	 breast	
cancer. Clin Cancer Res.	2012;18:6784-6791.
	30.	 Pohlmann	PR,	Mayer	IA,	Mernaugh	R.	Resistance	to	trastuzumab	in	
breast	cancer.	Clin Cancer Res.	2009;15:7479-7491.
	31.	 Hashida	S,	Yamamoto	H,	Shien	K,	et	al.	Acquisition	of	cancer	stem	
cell-like	properties	in	non-small	cell	lung	cancer	with	acquired	resis-
tance	to	afatinib.	Cancer Sci.	2015;106:1377-1384.
	32.	 Harbeck	N,	Huang	 CS,	Hurvitz	 S,	 et	 al.	 Afatinib	 plus	 vinorelbine	
versus	 trastuzumab	 plus	 vinorelbine	 in	 patients	with	HER2-over-
expressing	metastatic	 breast	 cancer	who	 had	 progressed	 on	 one	
previous	trastuzumab	treatment	(LUX-Breast	1):	an	open-label,	ran-
domised,	phase	3	trial.	Lancet Oncol.	2016;17:357-366.
	33.	 Sequist	LV,	Yang	JC,	Yamamoto	N,	et	al.	Phase	III	study	of	afatinib	or	
cisplatin	plus	pemetrexed	in	patients	with	metastatic	 lung	adeno-
carcinoma	with	EGFR	mutations.	J Clin Oncol.	2013;31:3327-3334.
	34.	 Abou-Alfa	GK,	Meyer	T,	Cheng	AL,	et	al.	Cabozantinib	in	patients	
with	advanced	and	progressing	hepatocellular	carcinoma.	N Engl J 
Med.	2018;379:54-63.
	35.	 Choueiri	 TK,	 Escudier	 B,	 Powles	 T,	 et	 al.	 Cabozantinib	 versus	
everolimus	 in	 advanced	 renal	 cell	 carcinoma	 (METEOR):	 final	 re-
sults	 from	 a	 randomised,	 open-label,	 phase	 3	 trial.	 Lancet Oncol. 
2016;17:917-927.
	36.	 Belsches-Jablonski	AP,	Biscardi	JS,	Peavy	DR,	Tice	DA,	Romney	DA,	
Parsons	SJ.	Src	family	kinases	and	HER2	interactions	in	human	breast	
cancer	cell	growth	and	survival.	Oncogene.	2001;20:1465-1475.
	37.	 Han	S,	Meng	Y,	Tong	Q,	et	al.	The	ErbB2-targeting	antibody	tras-
tuzumab	 and	 the	 small-molecule	 SRC	 inhibitor	 saracatinib	 syn-
ergistically	 inhibit	 ErbB2-overexpressing	 gastric	 cancer.	 mAbs. 
2014;6:403-408.
SUPPORTING INFORMATION
Additional	 supporting	 information	 may	 be	 found	 online	 in	 the	
Supporting	Information	section	at	the	end	of	the	article. 
How to cite this article:	Yoshioka	T,	Shien	K,	Takeda	T,	et	al.	
Acquired	resistance	mechanisms	to	afatinib	in	HER2-
amplified	gastric	cancer	cells.	Cancer Sci. 2019;110:2549–
2557. https	://doi.org/10.1111/cas.14089	
